【摘要】 目的探讨甲磺酸阿帕替尼联合替吉奥+奥沙利铂(SOX)方案三药转化治疗在一线治疗失败的晚期胃癌患者中的应用效果。方法选取2018年1月至2020年4月安徽省马鞍山市人民医院接收诊治的65例一线治疗失败的晚期胃癌患者为研究对象,按照随机数字表法将其分成对照组(SOX方案,33例)和研究组(甲磺酸阿帕替尼联合SOX方案,32例)。比较两组临床疗效、不良反应状况及1年生存率。结果研究组客观缓解率和临床获益率均明显高于对照组(P <0.05);研究组不良反应总发生率明显低于对照组(P <0.05);研究组1年生存率明显高于对照组(P <0.05)。结论一线治疗失败的晚期胃癌患者应用甲磺酸阿帕替尼联合SOX方案三药转化治疗的效果显著,明显提高客观缓解率和临床获益率,显著减少不良反应的同时,进一步提高1年生存率,值得推广。更多还原

【Abstract】 Objective To investigate the efficacy of Apatinib Mesylate combined with Tegafur+Oxaliplatin(SOX) regimen for three-drug conversion therapy in patients with advanced gastric cancer who failed first-line therapy. Methods A total of 65 patients with advanced gastric cancer who failed first-line treatment in Maanshan People’s Hospital,Anhui Province from January 2018 to April 2020 were selected as the research subjects. They were divided into control group(SOX regimen, 33 cases) and study group(Apatinib Mesylate combined with SOX regimen, 32 cases) according to random number table method. The clinical efficacy, adverse reactions and one-year survival rate of the two groups were compared. Results The objective remission rate and clinical benefit rate in the study group were significantly higher than those in the control group(P < 0.05). The total incidence of adverse reactions in the study group was significantly lower than that in the control group(P < 0.05). The one-year survival rate of the study group was significantly higher than that of the control group(P < 0.05). Conclusion Three-drug conversion therapy with Apatinib Mesylate combined with SOX regimen has a significant effect on advanced gastric cancer patients with first-line treatment failure, which significantly improves the objective remission rate and clinical benefit rate, significantly reduces adverse reactions, and further improves the one-year survival rate, which is worthy of promotion.更多还原